TP53 and cancer: Although research related to identifying new dual NFAT1-MDM2 inhibitors is accelerating, more work is needed to elucidate the binding affinity and specificity of the dual NFAT1-MDM2 inhibitors, the precise mechanisms underlying their activity in cancer cells with both wild-type and mutant p53, and also potential immune and other host toxicities that might arise during longer-term or repeated use.